Locations:
Search IconSearch

Deep Brain Stimulation After Stroke: What Underlies Improved Motor Function?

EDEN analysis investigates electrophysiological changes after continuous dentate nucleus stimulation

deep brain stimulation of dentate nucleus

Continuous deep brain stimulation of the dentate nucleus (DBS-DN) for four to eight months in stroke patients undergoing physical rehabilitation results in significant improvement in upper extremity function, and the improvement is accompanied by reduced cerebellar dependence for motor control. This finding, from a study of electrophysiological data from participants in the phase I EDEN trial, indicates that electrical stimulation deep in the cerebellum promotes cortical recovery in the area of the stroke lesion. The study was recently published in the Journal of Neuroscience.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The EDEN study design provided a unique opportunity to further investigate the underlying changes in the dentatothalamocortical pathway — an important network linking the cerebellum to the motor cortex — as a result of DBS-DN plus physical therapy,” says Raghavan Gopalakrishnan, PhD, MBA, of Cleveland Clinic’s Center for Neurological Restoration and a study author who led the electrophysiological investigations. “Our goal was to better understand how clinical improvement occurred in terms of brain function that could lead to objective biomarkers.”

“This project has given us exceptional insights into the function of a cerebello-cortical network after stroke and how DBS-DN modulates it,” adds the study’s senior and corresponding author, Andre Machado, MD, PhD, Chair of the Neurological Institute at Cleveland Clinic. “As participants improved, our results indicate that areas around the lesion in the cortex gained more function and depended less on the cerebellum for ordinary activities.”

EDEN – a successful phase I trial

The Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke (EDEN) trial (NCT02835443) — a single-arm, open-label study conducted at Cleveland Clinic — was a first-in-human study of DBS-DN for post-stroke rehabilitation. Its cohort consisted of 12 patients with a unilateral middle cerebral artery stroke that occurred one to three years prior to DBS-DN intervention and had resulted in moderate to severe upper extremity hemiparesis.

After implantation of the DBS lead, patients underwent four to eight months of continuous DBS-DN coupled with rehabilitation therapy, after which the lead was explanted. All patients who had at least minimal preservation of distal upper extremity motor function at baseline exceeded the threshold of clinical improvement after treatment, based on the Fugl-Meyer Assessment of upper extremity function and the Arm Motor Ability Test. Gains did not correlate with the time since stroke, and no serious perioperative or DBS-related adverse events occurred.

Advertisement

Trial results were published in Nature Medicine (2023;29[9]:2366-2374) and summarized in a ConsultQD post. EDEN set the stage for an ongoing multisite phase II trial, the RESTORE study (NCT05701280), which is expected to recruit 40 participants.

Current study investigates brain changes after DBS

The current study on electrophysiological correlates of motor improvements after DBS-DN therapy was based on data from the EDEN study. Motor testing using a visuomotor block-tracking task was conducted at two distinct times: (1) after implantation of electrodes but before DBS therapy commenced and (2) after DBS therapy was completed but before explantation.

The study design allowed investigators to do the following simultaneously:

  • Collect brain signals from the cortex with scalp EEG, creating a cortical map of brain activity
  • Collect local field potentials from externalized leads leading to the DN electrode implanted in the cerebellum, reflecting the neuronal activity in that area

“In this way, we could observe the effects of combined DBS and physical rehabilitation at both the perilesional cortex and the cerebellar DN, which are tightly interconnected by the dentatothalamocortical pathway,” Dr. Gopalakrishnan explains.

Findings show DBS helps normalize neural network patterns

Dr. Gopalakrishnan notes that in healthy individuals, the cerebellum is less active in the performance of routine tasks, such as lifting a cup of coffee to drink. However, if the cup starts to slip from one’s fingers, the cerebellum is activated for quick adjustment to avoid dropping it. In contrast, the cerebellum in stroke survivors is much more heavily involved in performing routine tasks, likely as a response to the motor impairment resulting from damage to the cortex.

Advertisement

Analysis of signals before and after DBS-DN and physical rehabilitation therapy revealed that the cerebellum became less involved in routine tasks and that activity increased in the perilesional cortex. So-called cortico-cerebellar coherence — i.e., neural communication between the DN and the perilesional cortex — was very high during routine repetitive motor tasks in patients at the time of implant and was much less pronounced at the conclusion of DBS therapy.

“The neurons destroyed by the stroke cannot be revived following therapy,” Dr. Gopalakrishnan says. “However, the perilesional cortex becomes more excitable following DN-DBS to pick up the majority of lost function, allowing the cerebellum to become less involved, which is what we might see if healthy individuals were to perform our task.”

He adds that the functional excitability of the DN and its connectivity with the ipsilesional cortex, especially in the low beta frequency, seem to be a predictor of motor outcomes following DBS-DN. This information is critical since it will allow the team to develop frequency-specific DBS.

“The electrophysiological findings from the EDEN study have given us an interesting window into mechanisms of motor improvement after DBS, and they support our therapeutic approach,” Dr. Machado concludes. “The EDEN trial has given hope to patients that significant gains are possible even years after a stroke, and it has taught us a little bit about how the brain responds to this novel treatment.”

This research was funded by the National Institutes of Health BRAIN initiative.

Advertisement

Related Articles

researcher in dark laboratory
September 12, 2024/Neurosciences/Research
Preclinical Imaging Research Aims to Help Refine Deep Brain Stimulation for Stroke Recovery

$3.2 million grant will fund use of calcium-based imaging to record neuronal activity in ischemia model

mobile stroke ambulance in front of a house
What We’ve Learned and Gained From 10 Years of Mobile Stroke Care

Insights and what’s next for the first U.S. mobile stroke unit to treat patients

older man being pushed in wheelchair
Study Documents Racial and Ethnic Gaps in Post-Acute Care for Stroke

Uninsured Hispanics least likely to be discharged to facility-based rehab or home healthcare

woman on stationary exercise cycle
July 1, 2024/Neurosciences/PM&R
New Trial to Assess Forced Exercise for Subacute Stroke Recovery

Research to test clinical efficacy and cost-effectiveness versus standard-of-care rehab

Cleveland Clinic Mobile Stroke Unit
Mobile Stroke Treatment Units Provide Faster Treatment for Acute Intracerebral Hemorrhage

Times to target blood pressure, CT and medication administration shorter than with EMS transport

23-NEU-4476409-CQD-Hero-650×450
January 11, 2024/Neurosciences/Epilepsy
Managing Seizure Risk After Stroke: Who Needs Antiseizure Meds, and for How Long?

Many patients unnecessarily continue the medications for years

23-NEU-4085912-CQD-Hero1-Whole-650×450
Probing the Neural Mechanisms of Parkinson’s Disease Motor Dysfunction

Research project will leverage insights into neural circuits to advance DBS technology

photo of old man with walker
Device-Aided Therapy Underutilized in Routine Care for Advanced Parkinson’s Disease

Study reveals heavy care burden, missed opportunities in patients with uncontrolled symptoms on oral therapy

Ad